AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Pharming Group (NASDAQ:PHAR – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Profitability
This table compares AbCellera Biologics and Pharming Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -248.83% | -17.49% | -12.36% |
| Pharming Group | 2.51% | 3.40% | 1.90% |
Earnings and Valuation
This table compares AbCellera Biologics and Pharming Group”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbCellera Biologics | $75.13 million | 47.22 | -$146.41 million | ($0.54) | -21.43 |
| Pharming Group | $376.13 million | 2.16 | $2.85 million | $0.12 | 95.50 |
Pharming Group has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for AbCellera Biologics and Pharming Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 4 | 1 | 2.71 |
| Pharming Group | 2 | 0 | 3 | 0 | 2.20 |
AbCellera Biologics currently has a consensus target price of $12.83, suggesting a potential upside of 10.92%. Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 237.41%. Given Pharming Group’s higher possible upside, analysts plainly believe Pharming Group is more favorable than AbCellera Biologics.
Insider and Institutional Ownership
61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
AbCellera Biologics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.
Summary
Pharming Group beats AbCellera Biologics on 8 of the 15 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
